Title:
MEDICINAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR PREVENTING PROGRESSION OF PHASE OF AMYOTROPHIC LATERAL SCLEROSIS
Document Type and Number:
WIPO Patent Application WO/2013/035712
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom associated with ALS, or preventing the progression of the phase of the symptom, and both of which can be particularly applied to patients who can be treated by the medicinal agent or the method highly effectively among ALS patients who are needed to be treated. According to the present invention, a medicinal agent which can be used for treating amyotrophic lateral sclerosis, preventing the progression of the phase of amyotrophic lateral sclerosis, treating a symptom associated with amyotrophic lateral sclerosis, or preventing the progression of the phase of the symptom is provided. The medicinal agent comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof as an active ingredient, is administered in such a manner that a 14-day dosing period and a 14-day washout period are repeated alternately or in such a manner that a 14-days initial dosing period and a subsequent 14-day initial washout period are set and subsequently a dosing period in which the dosing is carried out for any 10 days of 14 days and a 14-day washout period are repeated alternately, and is administered to a patient who meets specific criteria.
Inventors:
YONEOKA TAKATOMO (JP)
Application Number:
PCT/JP2012/072544
Publication Date:
March 14, 2013
Filing Date:
September 05, 2012
Export Citation:
Assignee:
MITSUBISHI TANABE PHARMA CORP (JP)
YONEOKA TAKATOMO (JP)
YONEOKA TAKATOMO (JP)
International Classes:
A61K31/4152; A61P11/16; A61P21/02; A61P21/04; A61P25/00; C07D231/26
Domestic Patent References:
| WO2005075434A1 | 2005-08-18 | |||
| WO2002034264A1 | 2002-05-02 | |||
| WO2002034264A1 | 2002-05-02 | |||
| WO2005075434A1 | 2005-08-18 |
Foreign References:
| EP0208874A1 | 1987-01-21 | |||
| JPH0531523B2 | 1993-05-12 | |||
| JPS63132833A | 1988-06-04 | |||
| JP2011062529A | 2011-03-31 |
Other References:
YOSHINO,H. ET AL.: "Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)", AMYOTROPHIC LATERAL SCLEROSIS, vol. 7, no. 4, 2006, pages 247 - 251, XP009134282
HIDE YOSHINO ET AL.: "Kin Ishukusei Sokusaku Kokasho (ALS) ni Taisuru edaravone o Mochiita Rinsho Shiken", NEUROLOGICAL THERAPEUTICS, vol. 20, no. 5, 2003, pages 557 - 564, XP008173239
TRAYNOR,B.J. ET AL.: "Clinical features of amyotrophic lateral sclerosis according to the E1 Escorial and Airlie House diagnostic criteria: A population-based study", ARCHIVES OF NEUROLOGY, vol. 57, no. 8, 2000, pages 1171 - 1176, XP055146043
SHINKEI CHIRYO, NEUROTHERAPEUTICS, vol. 20, no. 5, 2003, pages 557 - 564
"3. Grade Identification of Diagnostic Certainty, III. Diagnosis and/or Differential Diagnosis", ALS THERAPY GUIDELINE 2002, TREATMENT GUIDELINE OF THE SOCIETAS NEUROLOGICA JAPONICA, 2002
CRANIAL NERVE, vol. 53, no. 4, April 2001 (2001-04-01), pages 346 - 355
"VIII. Respiratory Management and/or Nutritional Management", ALS THERAPY GUIDELINE 2002, TREATMENT GUIDELINE OF THE SOCIETAS NEUROLOGICA JAPONICA, 2002
NEUROLOGY, vol. 64, 2005, pages 38 - 43
See also references of EP 2754440A4
HIDE YOSHINO ET AL.: "Kin Ishukusei Sokusaku Kokasho (ALS) ni Taisuru edaravone o Mochiita Rinsho Shiken", NEUROLOGICAL THERAPEUTICS, vol. 20, no. 5, 2003, pages 557 - 564, XP008173239
TRAYNOR,B.J. ET AL.: "Clinical features of amyotrophic lateral sclerosis according to the E1 Escorial and Airlie House diagnostic criteria: A population-based study", ARCHIVES OF NEUROLOGY, vol. 57, no. 8, 2000, pages 1171 - 1176, XP055146043
SHINKEI CHIRYO, NEUROTHERAPEUTICS, vol. 20, no. 5, 2003, pages 557 - 564
"3. Grade Identification of Diagnostic Certainty, III. Diagnosis and/or Differential Diagnosis", ALS THERAPY GUIDELINE 2002, TREATMENT GUIDELINE OF THE SOCIETAS NEUROLOGICA JAPONICA, 2002
CRANIAL NERVE, vol. 53, no. 4, April 2001 (2001-04-01), pages 346 - 355
"VIII. Respiratory Management and/or Nutritional Management", ALS THERAPY GUIDELINE 2002, TREATMENT GUIDELINE OF THE SOCIETAS NEUROLOGICA JAPONICA, 2002
NEUROLOGY, vol. 64, 2005, pages 38 - 43
See also references of EP 2754440A4
Attorney, Agent or Firm:
SIKs & Co. (JP)
Patent business corporation patent firm Sykes (JP)
Patent business corporation patent firm Sykes (JP)
Download PDF:
Claims:
Previous Patent: VEHICLE CONTROL APPARATUS
Next Patent: ANTENNA DEVICE AND COMMUNICATION TERMINAL DEVICE
Next Patent: ANTENNA DEVICE AND COMMUNICATION TERMINAL DEVICE